Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs 

JW makes public debut on Hong Kong exchange
In its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb Co. (NYSE:BMY) subsidiary Juno Therapeutics and WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) launched JW in 2016 to develop immuno-oncology cell therapies for cancer patients in China.

Fountain Healthcare Partners closes Fund III at €125M
With plans to invest in up to 10 private life science companies, Fountain Healthcare Partners closed its third fund at €125 million ($146.3 million). It had announced a €118 million first close in May 2019...